Dark Matter: Developing a Nanoantioxidant-Based Therapeutic System for AMD
Principal Investigator
Yongsu Kwon, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC, USA
About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$200,000
Active Dates
July 01, 2022 - August 30, 2024
Grant ID
M2022001F
Goals
Our research aims to develop a novel effective antioxidant system to prevent and suppress age-related macular degeneration (AMD) pathological progression by ceria-coated melanin nanoparticles (CMNPs).
Summary
In Aim 1, we will focus on the antioxidative activity of ceria-coated melanin nanoparticles (CMNPs) in scavenging against multiple primary and secondary reactive oxide and nitrogen species (RONS), and demonstrate cytotoxicity and treatment efficacy using RONS-induced mouse primary retinal pigmented epithelial (mRPE) cells. In Aim 2, we will demonstrate that CMNPs ensure a long-term sustained release of antioxidants for neutralizing oxidative stress, and relieve pathological damages in an Nrf2-/- -CNV of new dry and a wet AMD-like mouse model through a single-dose intravitreal administration.
Unique and Innovative
This work provides a strategy of combining melanin nanoparticles with traditional cerium oxide nanoparticles (ceria) for the treatment of AMD. The designed ceria-coated melanin nanoparticles (CMNPs) provide a powerful treatment option for oxidative stress-induced pathogenesis such as AMD by taking advantage of inherent antioxidant ability of melanin and ceria to create a unique synergistic approach. Our strategy will ensure the autoregenerative properties and more efficacious antioxidant activities of CMNPs for sustained therapy as robust reactive oxide and nitrogen species scavengers.
Foreseeable Benefits
This novel strategy is designed to overcome both forms of wet and dry AMD. Our findings will add a new, potentially powerful treatment option for patients with AMD, and be used in treatments for several other diseases, such as neurodegenerative disorders and diabetic retinopathy, which have oxidative stress in common and are challenged by current standard approaches. The designed ceria-coated melanin nanoparticles (CMNPs) could function as an alternative to natural melanin in RPE cells, providing insight into future directions as a novel approach to overcome dysfunction of melanin.
Related Grants
Macular Degeneration Research
Sterically Hindered Phenol, PMC, as a Potential Novel Therapeutic for Geographic Atrophy
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Suman Chaudhary, PhD
Current Organization
Schepens Eye Research Institute of Mass. Eye and Ear
Sterically Hindered Phenol, PMC, as a Potential Novel Therapeutic for Geographic Atrophy
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Suman Chaudhary, PhD
Current Organization
Schepens Eye Research Institute of Mass. Eye and Ear
Macular Degeneration Research
Studying Eye Blood Flow During Exercise to Understand the Origins of AMD
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Mark Draelos, MD, PhD
Current Organization
University of Michigan
Studying Eye Blood Flow During Exercise to Understand the Origins of AMD
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Mark Draelos, MD, PhD
Current Organization
University of Michigan
Macular Degeneration Research
Development of an Oral Treatment for Dry AMD Using Everyday Anti-Inflammatory Drugs
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Marco Bassetto, PhD
Current Organization
University of California, Irvine
Development of an Oral Treatment for Dry AMD Using Everyday Anti-Inflammatory Drugs
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Marco Bassetto, PhD
Current Organization
University of California, Irvine